By Fineline Cube 
AstraZeneca (AZ; NASDAQ: AZN) announced a strategic re‑alignment of its respiratory inhalation portfolio in China, consolidating the sales operations for Symbicort and Breztri under a single management umbrella. The move, revealed by William Tong, Assistant Vice‑President and Head of the Respiratory Inhalation Business Unit, aims to streamline go‑to‑market activities, accelerate product uptake, and strengthen cross‑functional collaboration across the region.
Personnel Changes
| New Role | New Appointee | Previous Title & Region | Report To |
|---|---|---|---|
| Executive Director, Symbicort National Marketing | Yu Junping | Executive Director, Symbicort East Region | William Tong |
| Head of Respiratory Inhalation Sales Operations | Wang Chengfeng | Acting Sales Director, Breztri East Region | William Tong |
| National Marketing Director, Symbicort (Outgoing) | Zhong Ying | – | – |
| – | – | – | – |
- Zhong Ying will depart AstraZeneca China on October 20, 2025 to pursue external opportunities.
- Yu Junping and Wang Chengfeng will assume dual reporting to William Tong, reinforcing a unified sales strategy for both inhalers.
Strategic Rationale
- Unified Brand Presence – Combining Symbicort’s well‑established asthma/COPD portfolio with Breztri’s emerging triple‑therapy platform creates a coherent respiratory offering that can be leveraged across physician segments.
- Operational Efficiency – Shared sales resources, joint field training, and consolidated customer insights reduce duplication and accelerate product penetration.
- Market Responsiveness – A single, agile sales organelle enables AstraZeneca China to adapt quickly to payer negotiations, emerging competitive dynamics, and evolving clinical guidelines.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech